Comparative Pharmacology
Head-to-head clinical analysis: CONRAY versus CONRAY 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY versus CONRAY 30.
CONRAY vs CONRAY 30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is an ionic, high-osmolality radiopaque contrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during radiographic procedures.
Iothalamate meglumine is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, providing vascular and organ opacification. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Intravenous: 20-60 mL for CT enhancement; intra-arterial: 5-80 mL per injection; concentration 282 mgI/mL (iothalamate meglumine). Dose based on procedure, body weight, and renal function.
Intravenous: 50-300 mL of a 30% solution (150-900 mg iodine/kg) as a single dose for contrast enhancement. Dosing depends on procedure and patient weight.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% biliary or fecal.
Renal (90-100% unchanged via glomerular filtration within 24 hours); minimal biliary/fecal (<1%)
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent